Company: AEAQ
Filing Date: 2025-08-29
Form Type: DRS
Source: 0001213900-25-081972
Chunk: 370

Company: Activate Energy Acquisition Corp.
Filing Date: 2025-08-29
Form: DRS
Chunk 370
---
 Section 4(a)(2) of the Securities Act. The number of founder shares outstanding was determined based on the expectation that the total size of this offering would be a maximum of 23,000,000 units if the underwriters’ over -allotmentoption is exercised in full and therefore that such founder shares would represent approximately 25% of the outstanding shares after this offering (not including the Class A ordinary shares that are included within the private units). Up to 1,000,000 of these shares will be surrendered for no consideration depending on the extent to which the underwriters’ over -allotmentis exercised.

II-1

Our sponsor is an accredited investor for purposes of Rule 501 of Regulation D. Each of the equity holders in our sponsor is an accredited investor under Rule 501 of Regulation D. The sole business of our sponsor is to act as the company’s sponsor in connection with this offering. The limited liability company agreement of our sponsor provides that its membership interests may only be transferred to our officers or directors or other persons affiliated with our sponsor, or in connection with estate planning transfers. Our sponsor and BTIG have committed, pursuant to written agreements, to purchase from us an aggregate of 585,000 private units (645,000 the underwriters’ over -allotmentoption is exercised in full) at $10.00 per unit (for an aggregate purchase price of $5,850,000 ($6,450,000 if the underwriters’ over -allotmentoption is exercised in full)). Of those 585,000 private units, our sponsor has agreed to purchase 385,000 private units (or 415,000 if the over -allotmentoption is exercised in full) and BTIG has agreed to purchase 200,000 private units (or 230,000 if the underwriters’ over -allotmentoption is exercised in full). The private units will also be worthless if we do not complete our initial business combination. This purchase will take place on a private placement basis simultaneously with the completion of our initial public offering. This issuance will be made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act. No underwriting discounts or commissions were paid with respect to such sales. Item 16. Exhibits and Financial Statement Schedules. Exhibit Index

| Exhibit No. |     | Description                                                                                                                           |
| 1.1*        |     | Form of Underwriting Agreement.                                                                                                       |
| 3